Improving outcomes for patients with acute myeloid leukemia in first relapse: A single center experience

Naveen Pemmaraju, Hagop Kantarjian, Guillermo Garcia-Manero, Sherry Pierce, Marylou Cardenas-Turanzas, Jorge Cortes, Farhad Ravandi

Research output: Contribution to journalArticle

Abstract

The outcome of patients with relapsed acute myeloid leukemia (AML) remains unsatisfactory, with few available effective therapies. Increased understanding of the biology of the disease has led to the identification of novel therapeutic agents, several of which have been evaluated in recently conducted clinical trials. We sought to determine whether the introduction of these agents as well as modern supportive care measures has already translated to better outcomes. We examined the outcomes of 1,056 patients with AML in first relapse treated between January 1993 and December 2013 at our institution. As previously reported, the independent prognostic factors for survival after first relapse included age at relapse, cytogenetics, and duration of first complete remission. Upon multivariable analysis, treatment era was an independent predictor of survival, with significant improvement in overall survival between 2008 and 2013 as compared to prior time periods. Modern supportive care measures as well as participation in clinical trials of novel agents are already improving the outcomes in first relapse.

Original languageEnglish (US)
Pages (from-to)27-30
Number of pages4
JournalAmerican Journal of Hematology
Volume90
Issue number1
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Recurrence
Survival
Clinical Trials
Cytogenetics
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Pemmaraju, N., Kantarjian, H., Garcia-Manero, G., Pierce, S., Cardenas-Turanzas, M., Cortes, J., & Ravandi, F. (2015). Improving outcomes for patients with acute myeloid leukemia in first relapse: A single center experience. American Journal of Hematology, 90(1), 27-30. https://doi.org/10.1002/ajh.23858

Improving outcomes for patients with acute myeloid leukemia in first relapse : A single center experience. / Pemmaraju, Naveen; Kantarjian, Hagop; Garcia-Manero, Guillermo; Pierce, Sherry; Cardenas-Turanzas, Marylou; Cortes, Jorge; Ravandi, Farhad.

In: American Journal of Hematology, Vol. 90, No. 1, 01.01.2015, p. 27-30.

Research output: Contribution to journalArticle

Pemmaraju, N, Kantarjian, H, Garcia-Manero, G, Pierce, S, Cardenas-Turanzas, M, Cortes, J & Ravandi, F 2015, 'Improving outcomes for patients with acute myeloid leukemia in first relapse: A single center experience', American Journal of Hematology, vol. 90, no. 1, pp. 27-30. https://doi.org/10.1002/ajh.23858
Pemmaraju, Naveen ; Kantarjian, Hagop ; Garcia-Manero, Guillermo ; Pierce, Sherry ; Cardenas-Turanzas, Marylou ; Cortes, Jorge ; Ravandi, Farhad. / Improving outcomes for patients with acute myeloid leukemia in first relapse : A single center experience. In: American Journal of Hematology. 2015 ; Vol. 90, No. 1. pp. 27-30.
@article{463617d83bdb4df4aa4e8edf35d6cb5c,
title = "Improving outcomes for patients with acute myeloid leukemia in first relapse: A single center experience",
abstract = "The outcome of patients with relapsed acute myeloid leukemia (AML) remains unsatisfactory, with few available effective therapies. Increased understanding of the biology of the disease has led to the identification of novel therapeutic agents, several of which have been evaluated in recently conducted clinical trials. We sought to determine whether the introduction of these agents as well as modern supportive care measures has already translated to better outcomes. We examined the outcomes of 1,056 patients with AML in first relapse treated between January 1993 and December 2013 at our institution. As previously reported, the independent prognostic factors for survival after first relapse included age at relapse, cytogenetics, and duration of first complete remission. Upon multivariable analysis, treatment era was an independent predictor of survival, with significant improvement in overall survival between 2008 and 2013 as compared to prior time periods. Modern supportive care measures as well as participation in clinical trials of novel agents are already improving the outcomes in first relapse.",
author = "Naveen Pemmaraju and Hagop Kantarjian and Guillermo Garcia-Manero and Sherry Pierce and Marylou Cardenas-Turanzas and Jorge Cortes and Farhad Ravandi",
year = "2015",
month = "1",
day = "1",
doi = "10.1002/ajh.23858",
language = "English (US)",
volume = "90",
pages = "27--30",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Improving outcomes for patients with acute myeloid leukemia in first relapse

T2 - A single center experience

AU - Pemmaraju, Naveen

AU - Kantarjian, Hagop

AU - Garcia-Manero, Guillermo

AU - Pierce, Sherry

AU - Cardenas-Turanzas, Marylou

AU - Cortes, Jorge

AU - Ravandi, Farhad

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The outcome of patients with relapsed acute myeloid leukemia (AML) remains unsatisfactory, with few available effective therapies. Increased understanding of the biology of the disease has led to the identification of novel therapeutic agents, several of which have been evaluated in recently conducted clinical trials. We sought to determine whether the introduction of these agents as well as modern supportive care measures has already translated to better outcomes. We examined the outcomes of 1,056 patients with AML in first relapse treated between January 1993 and December 2013 at our institution. As previously reported, the independent prognostic factors for survival after first relapse included age at relapse, cytogenetics, and duration of first complete remission. Upon multivariable analysis, treatment era was an independent predictor of survival, with significant improvement in overall survival between 2008 and 2013 as compared to prior time periods. Modern supportive care measures as well as participation in clinical trials of novel agents are already improving the outcomes in first relapse.

AB - The outcome of patients with relapsed acute myeloid leukemia (AML) remains unsatisfactory, with few available effective therapies. Increased understanding of the biology of the disease has led to the identification of novel therapeutic agents, several of which have been evaluated in recently conducted clinical trials. We sought to determine whether the introduction of these agents as well as modern supportive care measures has already translated to better outcomes. We examined the outcomes of 1,056 patients with AML in first relapse treated between January 1993 and December 2013 at our institution. As previously reported, the independent prognostic factors for survival after first relapse included age at relapse, cytogenetics, and duration of first complete remission. Upon multivariable analysis, treatment era was an independent predictor of survival, with significant improvement in overall survival between 2008 and 2013 as compared to prior time periods. Modern supportive care measures as well as participation in clinical trials of novel agents are already improving the outcomes in first relapse.

UR - http://www.scopus.com/inward/record.url?scp=84919607949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919607949&partnerID=8YFLogxK

U2 - 10.1002/ajh.23858

DO - 10.1002/ajh.23858

M3 - Article

C2 - 25251041

AN - SCOPUS:84919607949

VL - 90

SP - 27

EP - 30

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 1

ER -